Interleukin-17A Antagonist

Interleukin-17A Antagonists

Ankylosing Spondylitis

Psoriatic Arthritis

<section class="Section" data-sectioncode="34089-3"><a name="section-10"></a><h1>11     DESCRIPTION</h1>Secukinumab, a recombinant human monoclonal IgG1/κ antibody, is an interleukin-17A antagonist. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Secukinumab has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains.COSENTYX InjectionCOSENTYX injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous use. COSENTYX is supplied in a single-dose Sensoready pen with a 27-gauge fixed ½-inch needle, or a single-dose prefilled syringe with a 27-gauge fixed ½-inch needle. The removable cap of the COSENTYX Sensoready pen or prefilled syringe contains natural rubber latex.Each COSENTYX Sensoready pen or prefilled syringe contains 150 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (3.103 mg), L-methionine (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.Each COSENTYX 75 mg/0.5 mL prefilled syringe contains 75 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (1.552 mg), L-methionine (0.373 mg), polysorbate 80 (0.1 mg), trehalose dihydrate (37.83 mg), and Sterile Water for Injection, USP, at pH of 5.8. COSENTYX for InjectionCOSENTYX for injection is supplied as a sterile, preservative free, white to slightly yellow, lyophilized powder in single-dose vials for subcutaneous use after reconstitution. Each COSENTYX vial contains 150 mg of secukinumab formulated in L-histidine/histidine hydrochloride monohydrate (4.656 mg), polysorbate 80 (0.6 mg), and sucrose (92.43 mg). Following reconstitution with 1 mL Sterile Water for Injection, USP, the resulting pH is approximately 5.8.</section>

COSENTYX

0.5 ML secukinumab 150 MG/ML Prefilled Syringe

0.5 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

1 ML secukinumab 150 MG/ML Auto-Injector

1 ML secukinumab 150 MG/ML Auto-Injector [Cosentyx]

1 ML secukinumab 150 MG/ML Prefilled Syringe

1 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

Cosentyx

secukinumab

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="section-8"></a><h1>11 DESCRIPTION</h1>Risankizumab-rzaa, an interleukin-23 (IL-23) antagonist, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Risankizumab-rzaa is produced by recombinant DNA technology in Chinese hamster ovary cells and has an approximate molecular weight of 149 kDa. SKYRIZI (risankizumab-rzaa) injection 75 mg/0.83 mL prefilled syringe for subcutaneous useEach SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each syringe delivers 75 mg of risankizumab-rzaa, and the inactive ingredients polysorbate 20 (0.17 mg), sodium succinate (0.53 mg), sorbitol (34 mg), succinic acid (0.049 mg), and Water for Injection, USP. The pH is 6.2.SKYRIZI (risankizumab-rzaa) injection 90 mg/mL prefilled syringe for subcutaneous useEach SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each syringe delivers 90 mg of risankizumab-rzaa, and inactive ingredients polysorbate 20 (0.2 mg), sodium succinate (0.63 mg), sorbitol (41 mg), succinic acid (0.059 mg), and Water for Injection, USP. The pH is 6.2.SKYRIZI (risankizumab-rzaa) injection 150 mg/mL prefilled syringe or prefilled pen for subcutaneous use Each SKYRIZI prefilled pen or prefilled syringe contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each syringe and pen delivers 150 mg of risankizumab-rzaa and the inactive ingredients glacial acetic acid (0.054 mg), polysorbate 20 (0.2 mg), sodium acetate (0.75 mg), trehalose (63.33 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI (risankizumab-rzaa) injection 180 mg/1.2mL (150 mg/mL) prefilled cartridge for use with supplied on-body-injector for subcutaneous useEach SKYRIZI prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 180 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.065 mg), polysorbate 20 (0.24 mg), sodium acetate (0.9 mg), trehalose (76 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI (risankizumab-rzaa) injection 360 mg/2.4 mL (150 mg/mL) prefilled cartridge for use with the supplied on-body injector for subcutaneous use Each SKYRIZI prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 360 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.13 mg), polysorbate 20 (0.48 mg), sodium acetate (1.8 mg), trehalose (152 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI 600 mg/10 mL (60 mg/mL) in a vial for intravenous infusionSKYRIZI (risankizumab-rzaa) injection 600 mg/10 mL (60 mg/mL) is a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution in a 10 mL single-dose vial.Each 10 mL single-dose vial contains 600 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.54 mg), polysorbate 20 (2 mg), sodium acetate (7.5 mg), trehalose (633.3 mg), and Water for Injection, USP. The pH is 5.7.</section>

Skyrizi

0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe

0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe [Skyrizi]

1 ML risankizumab-rzaa 150 MG/ML Auto-Injector

1 ML risankizumab-rzaa 150 MG/ML Auto-Injector [Skyrizi]

1 ML risankizumab-rzaa 150 MG/ML Prefilled Syringe

1 ML risankizumab-rzaa 150 MG/ML Prefilled Syringe [Skyrizi]

1.2 ML risankizumab-rzaa 150 MG/ML Cartridge

1.2 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi]

10 ML risankizumab-rzaa 60 MG/ML Injection

10 ML risankizumab-rzaa 60 MG/ML Injection [Skyrizi]

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi]

risankizumab

Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the initial loading dose, subcutaneous injection of Cosentyx is required every four weeks, but patients can typically be taught to self-administer using the Sensoready pen or prefilled syringe. Nasopharyngitis and an elevated risk of infection are the most frequently reported side effects.

Cosentyx is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondylarthritis, and Enthesitis-related Arthritis. 


Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Online Sample Form 

Reimbursement Information 

Billing & Coding Guide 

Consentyx Connect Start Form 

Cosentyx Connect Start Form - Spanish

Coverage Authorization Request: Plaque Psoriasis 

Coverage Authorization Appeals: Plaque Psoriasis

Letter of Medical Necessity: Plaque Psoriasis

Formulary Exception Request Letter: Plaque Psoriasis 

Tiering Exception Request Letter: Plaque Psoriasis

Coverage Authorization Request: Psoriatic Arthritis

Coverage Authorization Appeals: Psoriatic Arthritis 

Letter of Medical Necessity: Psoriatic Arthritis 

Formulary Exception Request Letter: Psoriatic Arthritis 

Tiering Exception Request Letter: Psoriatic Arthritis 

Dosage Appeals Letter: Psoriatic Arthritis 

Coverage Authorization Request: Ankylosing Spondylitis 

Coverage Authorization Appeals: Ankylosing Spondylitis 

Letter of Medical Necessity: Ankylosing Spondylitis 

Formulary Exception Request Letter: Ankylosing Spondylitis 

Tiering Exception Request Letter: Ankylosing Spondylitis 

Dosage Appeals Letter: Ankylosing Spondylitis 

Coverage Authorization Request: nr-axSpA

Coverage Authorization Appeals:  nr-axSpA

Letter of Medical Necessity:  nr-axSpA

Formulary Exception Request Letter:  nr-axSpA

Tiering Exception Request Letter: nr-axSpA

Dosage Appeals Letter:  nr-axSpA

Coverage Authorization Request: JPsa & ERA

Coverage Authorization Appeals: JPsa & ERA

Letter of Medical Necessity: JPsa & ERA

Formulary Exception Request Letter: JPsa & ERA

Tiering Exception Request Letter: JPsa & ERA

Dosage Appeals Letter: JPsa & ERA

Coverage Authorization Request: PsA with PsO

Coverage Authorization Appeals: PsA with PsO

Letter of Medical Necessity : PsA with PsO

Formulary Exception Request Letter: PsA with PsO

Tiering Exception Request Letter: PsA with PsO

Medical Exception Request Letter 

Efficacy: Plaque Psoriasis 

Safety Profile: Plaque Psoriasis 

Efficacy & Safety Profile: Plaque Psoriasis (Pediatric)

Efficacy (Clinical Manifestations): Psoriatic Arthritis 

Efficacy (Radiographic Progression): Psoriatic Arthritis 

Efficacy (MDA): Psoriatic Arthritis 

Efficacy (HAQ-DI): Psoriatic Arthritis 

Efficacy (Fatigue): Psoriatic Arthritis 

Safety Profile: Psoriatic Arthritis 

Efficacy (Disease Hallmarks): Ankylosing Spondylitis

Efficacy (hsCRP): Ankylosing Spondylitis 

Efficacy (ASDAS-CRP): Ankylosing Spondylitis 

Safety Profile: Ankylosing Spondylitis 

Efficacy (Disease Hallmarks): nr-axSpA

Efficacy (SI Joint Edema): nr-axSpA

Efficacy (hsCRP): nr-axSpA

Safety Profile: nr-axSpA

Efficacy (Time to Flare): JPsA

Efficacy (JIA ACR): JPsA

Efficacy (Enthesitis/Dacylitis): JPsA

Efficacy (Disease Activity): JPsA

Efficacy (Skin Clearance): JPsA

Safety Profile: JPsA/ERA

Efficacy (Time to Flare): ERA

Efficacy (JIA ACR): ERA

Efficacy (Enthesistis/Dacylitis): ERA

Efficacy (Disease Activity): ERA

Dosing: All Indications

Enroll in Patient Savings Program 

Enroll in Bridge Program 

Cosentyx Patient Assistance Program Income Requirements 

Novartis Patient Assistance Foundation Application - English

Novartis Patient Assitance Foundation Application - Spanish 

Cosentyx Connect Support Program

Sharps Container 

About Cosentyx: Plaque Psoriasis 

FAQs: Plaque Psoriasis

Patient Stories: Plaque Psoriasis 

Twill Care App: Plaque Psoriasis

Taking Cosentyx: Plaque Psoriasis

Side Effects

Doctor Discussion Guide: PsA, PsO, AS, nr-axSpA

About Cosentyx: Psoriatic Arthritis 

FAQs: Psoriatic Arthritis 

Patient Stories: Psoriatic Arthritis 

Patient Resources: Psoriatic Arthritis 

Taking Cosentyx: Psoriatic Arthritis 

About Cosentyx: Ankylosing Spondylitis

Patient Stories: Ankylosing Spondylitis

FAQs: Ankylosing Spondylitis 

Taking Cosentyx: Ankylosing Spondylitis 

About Cosentyx: nr-axSpA

FAQs: nr-axSpA 

Taking Cosentyx: nr-axSpA

About Cosentyx: Pediatric Psoriasis 

Skyrizi, an interleukin inhibitor, is prescribed to alleviate inflammation associated with plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. The recommended dose is 150mg administered every 12 weeks as two subcutaneous injections of 75mg, which patients can learn to self-administer. The most frequently reported side effects are upper respiratory tract infections, headache, and fatigue.

Skyrizi is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, and Crohn’s Disease. 


Billing and Coding Guide 

Formulary Information

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity 

Formulary Exception Letter 

Tiered Exception Letter 

HIPAA Authorization Template

Navigating PA 

Guide To Starting Skyrizi 

Skyrizi Complete Prescription & Enrollment Form: Rheumatology & Dermatology 

Skyrizi Complete Prescription & Enrollment Form: Gastroenterology

Complete by Abbvie {HCP Portal}

Enroll in Patient Savings Program

Abbvie Patient Assistance Program Application - English 

Abbvie Patient Assistance Program Application - Spanish 

Mechanism of Action (MOA)

Efficacy (PASI): Plaque Psoriasis 

Efficacy (Challenging Body Areas): Plaque Psoriasis 

Efficacy (Before & After): Plaque Psoriasis 

Efficacy (vs Cosentyx): Plaque Psoriasis 

Efficacy (vs Stelara): Plaque Psoriasis 

Efficacy (vs Humira): Plaque Psoriasis 

Efficacy in PsA for Dermatologists 

Dosing: Plaque Psoriasis 

Injection Devices: Plaque Psoriasis  & Psoriatic Arthritis 

Safety Profile: Plaque Psoriasis & Psoriatic Arthritis 

Other HCP Resources: Plaque Psoriasis 

Skyrizi Complete App 

Efficacy (ACR Data): Psoriatic Arthritis 

Efficacy (Enthesitis-Dactylitis): Psoriatic Arthritis 

Efficacy (Disease Control): Psoriatic Arthritis 

Dosing: Psoriatic Arthritis 

Other HCP Resources: Psoriatic Arthritis 

Efficacy: Crohn's Disease

Safety Profile: Crohn's Disease

Dosing & Administration: Crohn's Disease

Other HCP Resources: Crohn's Disease

Patient Brochure: Plaque Psoriasis 

Quick Tips For Self Injecting - 150mg Pen 

Quick Tips For Injecting - 150mg Prefilled Syringe

Skyrizi Complete Support Program 

Nurse Ambassador 

About Skyrizi: Plaque Psoriasis 

Taking Skyrizi: Plaque Psoriasis & Psoriatic Arthritis 

Side Effects: Plaque Psoriasis & Psoriatic Arthritis 

Before and After: Plaque Psoriasis 

Patient Stories: Plaque Psoriasis

Doctor Discussion Guide: Plaque Psoriasis & Psoriatic Arthritis 

Prep For Your Appointment: Plaque Psoriasis & Psoriatic Arthritis 

Instructions For Use: Plaque Psoriasis 

Instructions For Use: Psoriatic Arthritis 

About Skyrizi: Psoriatic Arthritis 

About Skyrizi: Crohn's Disease 

Taking Skyrizi: Crohn's Disease 

Side Effects: Crohn's Disease 

Doctor Discussion Guide: Crohn's Disease 

Infusion Support: Crohn's Disease 

Infusion Prep Guide: Crohn's Disease 

On-Body Injector (OBI) Prep Guide: Crohn's Disease

Instructions For Use: Crohn's Disease 

Infusion To On-Body Injector (OBI) Guide 

Taltz

Stelara

Tremfya

Cosentyx®(secukinumab)	Skyrizi®(risankizumab)

Prescription Only Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the...	Prescription Only Skyrizi, an interleukin inhibitor, is prescribed to alleviate inflammation associated with plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. The recommended...
Dosage & Administration
Administration
Subcutaneous Injection. Learn more.	Subcutaneous Injection. Learn more.
Dosing
* With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. * Without a loading dosage: 150 mg every 4 weeks.. Learn more.	150 mg at Week 0, Week 4, and every 12 weeks thereafter.. Learn more.
Latin Shorthand
W/ Loading Dose: 150mg Wks 0,1,2,3,4, then q4wks. W/o Loading Dose: 150mg q4wks.. Learn more.	150 mg Week 0, 4 then q12w. Learn more.
Adverse Reactions
Most common adverse reactions (> 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. . Learn more.	Most common adverse reactions are: • Plaque Psoriasis and Psoriatic Arthritis (≥ 1%): upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. • Crohn’s Disease (>3%): o Induction: upper respiratory infections, headache, and arthralgia. o Maintenance: arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy, and urinary tract infection. . Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$5. Learn more.
Annual Cap
Learn more.	$6,000. Learn more.
Assistance Expiration
Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available

Cosentyx® Alternatives